Podcasts about Winfrey

In this timely episode of "Hip Hop Can Save America!," Dr. Adia Winfrey dives deep into the chaos and injustice surrounding Alabama's recent redistricting battles. The founder of H.Y.P.E. Hip Hop Therapy and Transform Alabama breaks down how political maneuvers and Supreme Court decisions have affected Black voters and the broader fight for democracy. “Alabama is about 27% black. So you would think that a congressional map would represent such...but it didn't do that,” she explains, highlighting the real-world consequences of these legal battles. Dr. Winfrey offers a front-row perspective on how grassroots organizers are using Hip Hop culture to inspire both dialogue and action at the community level. She reveals the power that music and culture have to ignite civic participation: “We use Hip Hop as a way to bring people together...when we draw people out, we just have conversations with people. Because everything is political, whatever you want to talk about, it goes back to some elected official doing something that impacted that." If you want unfiltered insights into how Hip Hop is mobilizing voters and shining a light on the future of democracy in the South, you won't want to miss this powerful conversation. https://www.transformalabama.org https://www.instagram.com/transformalabama---If you're looking for Hip Hop news with context, history, and care, you're in the right place.

Elijah gets you caught up on his past week, & answers your Mother's Day questions.

The U.S. and Iran have exchanged fire amid a fragile ceasefire. Iranian state media claims Iran's navy fired warning shots at American destroyers. Meanwhile, the U.S. military said it shot down Iranian cruise missiles and drones, and sank multiple Iranian small boats. Holly Williams reports. Supreme Court Justice Neil Gorsuch told Jan Crawford his loyalty is to the "Constitution and laws of the United States," when asked if a justice owes a president loyalty following President Trump's attacks towards the high court. He also addressed the climate of today's Supreme Court and his new children's book. Freya India, a Substack writer who focuses on women and technology, says Gen Z women have grown up seeing themselves as "an object in a marketplace." She talks to "CBS Mornings" about how she thinks social media and tech companies have amplified the generation's anxieties and her hope for the future. Stars shined at fashion's biggest night of the year on Monday, the Met Gala. This year's event was co-chaired by Beyoncé, Nicole Kidman and Venus Williams. Outside the museum, protesters gathered holding letters that spelled out "tax the rich." Adriana Diaz reports. GAP Inc. executive vice president and creative director Zac Posen discusses designing model Kendall Jenner's dress for this year's Met Gala. He also dives into other looks that stood out at the annual event. Oprah Winfrey exclusively announced on "CBS Mornings" her latest book club selection, "John of John" by Douglas Stuart, who called having his book picked by Winfrey "mind blowing." "CBS Mornings" reveals the nominees for six major categories for the 79th annual Tony Awards, which air June 7 on CBS. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Elijah opens the show talking about the supreme court's voting decision. He gets you caught up on his past week, & answers your email questions. Be sure to tune in.

Elijah is back, fresh off vacation! Elijah gets you caught up on his past two weeks aways, & keeping with the autism awareness month theme, he answers a question from a loyal listener about her recent challenges raising her two children on the spectrum. Be sure to tune in.

This special Tick Boot Camp Podcast crossover features the full International Lyme and Associated Diseases Society (ILADS) webinar recording, “At the Frontlines of Chronic Illness: Conversations with ILADS Experts.” In this dynamic panel discussion, leading clinicians and specialists unpack why Lyme disease and other infection-associated chronic illnesses are so misunderstood, why testing fails so many patients, and what it really takes to heal—brain, immune system, mitochondria, and terrain included. Moderated by Rich Johannesen (Tick Boot Camp), the panel delivers practical insights and hopeful, patient-centered guidance for anyone navigating complex chronic illness—whether you're a patient, caregiver, clinician, or advocate. Featured Panelists Chris Winfrey, MD — Psychiatrist; Medical Director, New Image Wellness Nicole Bell — “The Lyme Disease Engineer”; CEO, Galaxy Diagnostics Tania Dempsey, MD — Medical Director, AIM Center for Personalized Medicine Melanie Stein, ND — Naturopathic Doctor; Author focused on cellular wellness and healing terrain Host/Moderator: Rich Johannesen (Tick Boot Camp) ILADS Intro: Ali Moresco (ILADS) Episode Highlights ILADS Mission and Why This Webinar Matters The webinar opens with ILADS' mission: improving diagnosis and treatment of Lyme disease and associated illnesses through research, education, and policy. ILADS emphasizes physician training and patient-centered care, while also supporting the educational mission of ILADEF. Rich frames the night as a rare opportunity to hear from experts working at the front lines of complex chronic illness—especially for patients who've been dismissed, misdiagnosed, or told their symptoms “don't make sense.” Segment 1: Brain Health, Neuroimmune Illness, and Why Lyme “Feels Like Dementia” Chris Winfrey, MD Dr. Winfrey introduces a core theme: Lyme is not only an infection—it often behaves like a neuroimmune illness. Key takeaways: The brain is a high-energy, high-immune-demand organ, uniquely vulnerable to infection-driven inflammation and toxicity. Lyme can disrupt brain function through: Blood flow issues Synaptic dysfunction Myelin damage Network-level disruption, not just “neurotransmitters” He describes brain function through networks that Lyme can destabilize: Default Mode Network (internal reflection) Salience Network (switching between networks) Central Executive Network (planning/organization) Action Network (execution) Autonomic Network (regulation) Limbic Network (threat/fear response) The result: patients often describe “brain shutdown,” confusion, cognitive impairment, and even dementia-like symptoms. A major reframing: Emotions are not “non-physical.” They are measurable physiological states. Lyme-driven nervous system injury can create emotional disturbance because the biology is disturbed. Segment 2: Poly-microbial Infection, Fight-or-Flight, and the Belief-Healing Loop Winfrey + Rich Discussion Rich frames humans as spiritual, emotional, and physical beings, and asks how chronic infection impacts both body and emotional resilience. Key points: Lyme can cross the blood-brain barrier and affect virtually any organ system. The nervous system becomes a “central battleground,” and measurement is hard because nervous system dysfunction isn't captured well by simple bloodwork. Rich and Dr. Winfrey explore how illness disrupts perception, decision-making, and our ability to interpret the world—especially when gut function and intuition feel “offline.” The healing paradox: Chronic stress and “fighting your way to healing” can backfire. Dr. Winfrey emphasizes that healing requires a parasympathetic state—rest, digest, repair—and that this often involves acceptance, surrender, trust, and safety. Segment 3: The State of Testing—Why So Many Patients Test Negative Nicole Bell (Galaxy Diagnostics) Nicole shares her personal motivation and professional mission: testing determines treatment, reimbursement, and belief—and too many patients are failed by existing tools. Indirect testing (antibody testing): The standard approach relies on antibodies—meaning it depends on the immune system behaving predictably. But Lyme and other stealth pathogens evade and suppress immune responses. Even in controlled research models, two infected subjects can show completely different antibody patterns. Immunosuppression (illness severity, medications like steroids, immune dysregulation) can reduce antibody reliability. Direct testing (pathogen detection):Nicole contrasts Lyme testing with illnesses like COVID—where you use tests that look for the pathogen itself (PCR/antigen), not just antibodies. Why direct detection is hard in Lyme: Pathogens can be low abundance They can be tissue-sequestered Sampling matters Why urine can matter for Lyme: Lyme may not stay in blood, but it can shed proteins/antigens that filter into urine. Galaxy's approach includes methods to capture, concentrate, and detect those markers. New diagnostics focus: Genus-level screening for the “3Bs” (Borrelia, Bartonella, Babesia) Reducing guessing when symptoms overlap and co-infections “masquerade” as each other Segment 4: Immune Dysfunction, Mast Cells, and Why Antibody Testing Can Go Haywire Tania Dempsey, MD (AIM Center for Personalized Medicine) Dr. Dempsey explains the immune system through two major branches: Innate immune system (fast, primitive defense) Adaptive immune system (antibodies, longer-term response) Mast cells as first responders: Mast cells detect “danger” and release inflammatory mediators (histamine and many others). In chronic infection, mast cells can remain persistently activated, releasing hundreds of inflammatory compounds. Why antibody tests fail (two patterns): Immune suppression → insufficient antibody production → false negatives Immune chaos → excessive, inappropriate antibody production → confusing positives - Positive Lyme bands “everywhere” - Positive autoantibodies without classic autoimmune disease patterns - “Everything looks positive” because signaling is dysfunctional Her central philosophy:It's not only about killing the bug. It's about fixing immune regulation so the body can actually clear or control infection. She also names the broader context: modern toxic load (mold, plastics, pesticides, “forever chemicals”) primes the immune system into dysregulation before infections even arrive. Segment 5: Advanced Immune-Modulating Tools Therapeutic Plasma Exchange + SOT Dr. Dempsey discusses therapies she's excited about, especially for complex, stuck cases: Therapeutic Plasma Exchange (TPE / plasmapheresis): Removes plasma (where antibodies, inflammatory mediators, and “garbage” accumulate) Replaces with albumin (and sometimes IVIG) Concept: reduce inflammatory burden + toxic load to reset the terrain SOT (Supportive Oligonucleotide Technique): Molecular targeted approach designed to reduce replication of specific pathogens More targeted than “wide-net” antimicrobial approaches Used strategically after lowering inflammatory/toxic burden She emphasizes: not for everyone, not a universal cure—but promising enough to merit formal publication. Segment 6: GLP-1 Agonists and Mast Cell Stabilization “Brain-melt” moment, revisited Dr. Dempsey explains why drugs commonly known for diabetes/weight loss may have immune benefits: Mast cells have receptors for GLP and GIP hormones Patients showed improvements beyond weight: cognitive function, inflammation, immune stability She describes: Semaglutide (Ozempic/Wegovy) Tirzepatide (Mounjaro/Zepbound) Emerging triple agonists (GLP-1/GIP/glucagon pathways) Her clinical approach has moved these agents earlier in care plans for immune stabilization in select cases. Segment 7: Cellular Healing, Mitochondria, and the Terrain Melanie Stein, ND Dr. Stein brings it home: healing often stalls when we focus only on killing pathogens, but don't repair the cellular damage. Core concepts: Lyme damages cell membranes, disrupting what goes in/out and how cells communicate. It contributes to mitochondrial dysfunction, reducing ATP (energy currency). If cells stay in “alarm mode,” healing remains blocked. Cell membrane therapy and terrain support: IV and oral lipid support (phospholipids, phosphatidylcholine, omega fatty acids) Personalized support based on lipidomic patterns Supportive therapies to reduce oxidative stress and “toxic fats” Focus on signaling safety to the body—so repair can resume Cell Danger Response:A key theme: even after infections reduce, the body may remain stuck in a persistent defense state, requiring cellular and nervous system support to exit “danger mode.” Regulation Before Eradication Panel Reflection Round As the panel closes, several themes converge: Limbic system + autonomic nervous system regulation is foundational “Regulation becomes before eradication” Healing requires safety, predictability, and nervous system calm Chronic illness can block our ability to connect—especially in relationships—because survival physiology dominates Dr. Dempsey adds that limbic retraining / nervous system reset is often the first step she starts with in her practice. Question and Answer Highlights Lyme and Cancer? The panel notes emerging signals connecting tick-borne illness and certain cancers, but emphasizes that more research is needed to determine causality. Herniated discs, connective tissue, and chronic infection The discussion highlights potential links through: connective tissue disruption collagen damage mast cell mediators (enzymes that affect tissue integrity) infection-driven inflammation Cross-reactive antibody results (example: Brucella) The group explains how antibody testing can produce confusing results due to immune dysregulation and cross-reactivity—another reason why interpretation and test methodology matter. Nasal testing / sinus terrain While not a mainstream Lyme diagnostic route, the panel references nasal/sinus colonization (especially with mold-related or chronic inflammatory patterns) as a terrain factor that can influence recovery. Resources Mentioned Center for Lyme Action – State of Lyme Disease Research paper (Nicole Bell collaboration) ILADS Provider Search International Lyme and Associated Diseases Educational Foundation (ILADEF) Donations (supports education and clinician training) Final Message to Listeners This episode is a reminder that Lyme disease and infection-associated chronic illness are not one-dimensional problems. The path forward often requires: better diagnostics immune regulation nervous system support cellular repair personalized care and hope that the body can recover when the right puzzle pieces come together

Today on the show, we're bringing you a recent conversation Tristan and Aza had with Oprah Winfrey on her podcast, The Oprah Podcast, taped in front of a live studio audience. Tristan and Aza first met Oprah as guests on her 2024 special, "AI and the Future of Us," which offered an introduction to the AI Dilemma. This conversation goes much deeper, giving a full picture of the profoundly anti-human future that our current path on AI is moving us toward — and what we can do to steer away from it. Tristan and Aza also did a Q+A with the audience, moderated by Oprah. Audience members shared their own experiences with AI and asked incisive, critical questions that you might have yourself. RECOMMENDED MEDIA See "The AI Doc" Read CHT's AI Roadmap Join The Human Movement Oprah's special "AI and the Future of Us" Watch Tristan's TED talkRECOMMENDED YUA EPISODES Here's Our Roadmap to a Better AI Future A Conversation with the Team Behind "The AI Doc" The AI Dilemma Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Elijah gets you caught up on his past week, & April is autism awareness & acceptance month. Elijah answers questions about this from listeners around the world.

In the past week, discussions around Ozempic and weight loss drugs have intensified, blending policy debates with celebrity health rumors. Minnesota lawmakers grappled with costs in the House Health Finance and Policy Committee, where a bill, HF4142, sponsored by Representative something, aimed to prohibit Medical Assistance coverage for prescription drugs used solely for weight loss like Ozempic. The measure was laid over, sparking questions on whether funding these medications saves money long-term by preventing obesity-related illnesses. According to the Minnesota House Session Daily report from late March 2026, supporters argued that covering such drugs now could reduce future expenses for comorbidities stemming from obesity.Oprah Winfrey remains at the center of Ozempic-related chatter, with fresh rumors about so-called Ozempic feet resurfacing after her appearances at Paris Fashion Week earlier this month. Nicki Swift reports that videos from the event showed Winfrey walking with slow, short steps, prompting online speculation that the GLP-1 drug, which she has used for weight management, weakened her muscles and caused sagging, veiny skin on her feet. Observers on X noted her frail gait at Stella McCartneys fashion show, dubbing it an Ozempic-induced shuffle similar to what others experience. Winfrey has not confirmed using Ozempic specifically but has praised GLP-1 medications openly. In past statements recalled amid this buzz, she described realizing thin people do not rely solely on willpower, as the drugs curb constant food thoughts, helping her maintain steady weight without yo-yoing.These side effects highlight risks of rapid weight loss, including premature aging appearances in areas like the neck and feet, as noted by experts analyzing similar cases with celebrities like Sharon Osbourne. Despite this, Winfrey expressed satisfaction with the tools impact on her life.Thanks for tuning in, listeners. Please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Elijah gets you caught up on his past week, & answers your questions about the TSA workers & the government shutdown.

Recent studies from the past week highlight new insights into Ozempic and similar GLP-1 medications for weight loss. Researchers from the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia analyzed large-scale data and found that semaglutide, the active ingredient in Ozempic, significantly reduces risks of depression, anxiety, and addiction alongside its weight loss effects. According to their work published in The Lancet Psychiatry, users experienced a 44 percent lower risk of depression and a 38 percent drop in anxiety disorders during treatment periods. Psychiatric hospital visits fell by 42 percent, and substance use disorders decreased by 47 percent compared to times without the medication. The team suggests these benefits may stem from lifestyle changes or direct effects on the brain.Another study from Washington University School of Medicine, reported by Fox News, warns that stopping GLP-1 drugs like Ozempic quickly erodes heart health gains. Continuous use over three years lowered cardiovascular risk by 18 percent through reductions in cholesterol, blood pressure, inflammation, and insulin resistance. However, quitting for six months raised risk by 4 percent, one year by 14 percent, and two years by 22 percent. Restarting the drugs provided partial protection, only 12 percent, indicating some lasting damage from discontinuation. Lead researcher Ziyad Al-Aly described this as metabolic whiplash, with silent reversals in metabolic health that could lead to heart attacks or strokes.Oprah Winfrey continues to draw attention for her weight loss transformation using GLP-1 medications. The List reports that recent before-and-after photos from events like the 2025 Tony Awards reveal Ozempic neck, a sagging, crepey skin effect under the jaw due to rapid fat loss outpacing skin adjustment. Winfrey has been seen favoring high-necked outfits to camouflage the loose folds, a common side effect among users.These developments underscore the dual-edged nature of Ozempic for weight management, offering mental and heart benefits during use but posing challenges with side effects and discontinuation.Thanks for tuning in, listeners, please subscribe, and remember, this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

A new study from the Cleveland Clinic, released this week, reveals that stopping weight-loss drugs like Ozempic and Mounjaro does not always lead to the rapid weight regain seen in earlier trials. Researchers analyzed nearly eight thousand patients who discontinued these injectable medications, known as GLP-one drugs, after using them for obesity or type two diabetes. Those treated for obesity lost an average of eight point four percent of their body weight before stopping and regained just zero point five percent after one year. For diabetes patients, the average loss was four point four percent before discontinuation, followed by an additional one point three percent loss over the next year. Many participants restarted the drugs, switched to alternatives, or turned to lifestyle changes like working with dietitians, helping them maintain or even improve their results. Hamlet Gasoyan, the lead researcher, noted that real-world flexibility in treatment plans explains why outcomes differ from strict clinical trials, where regain was over half the lost weight.However, another study from Washington University School of Medicine, also published this week, warns that halting these drugs can quickly erode heart health benefits. In tracking over three hundred thirty-three thousand veterans with type two diabetes, continuous three-year use reduced cardiovascular risks like heart attack and stroke by eighteen percent. Stopping for six months raised risk by four percent, one year by fourteen percent, and two years by twenty-two percent. Restarting offered partial protection at twelve percent reduction, but not full recovery. Researcher Ziad Al-Aly described this as metabolic whiplash, with rising cholesterol, blood pressure, and inflammation that silently builds danger.Oprah Winfrey, who has openly discussed her use of GLP-one medications for weight loss, continues to show visible effects in recent appearances. Photos from events like Paris Fashion Week earlier this year highlight what observers call Ozempic neck, loose skin under the jaw from rapid fat loss. Winfrey has favored high-neck outfits to address it, and some recent images suggest possible skin treatments are improving the appearance. She previously shared that the drugs made her feel more alive, stressing the need to start slowly to avoid side effects.These findings underscore the value of ongoing medical guidance for long-term success with Ozempic and similar drugs. Thanks for tuning in, listeners, please come back next week for more. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Elijah gets you caught up on his past week & answers your email questions.

 **Oprah Winfrey Responds to Criticism Over Paris Fashion Week Appearance**Oprah Winfrey has addressed backlash regarding her appearance at Paris Fashion Week, where she looked notably thin and appeared to struggle while walking. So they were dragging me and Gayle saying, 'Look at them walking like they're 90 years old,'" Winfrey said in response to online criticism. One commenter noted, "Folks don't bend over when they can't see, they squint," while another remarked on Winfrey's noticeable changes in behavior following her weight loss, suggesting she was "all about the outside."Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Elijah gets you caught up on his past week, & answers your email questions.

A new study from UT Southwestern Medical Center, reported by HealthDay News on March 12, reveals that people often switch between GLP-1 weight-loss drugs like Ozempic and Zepbound within the first year of treatment. Researchers analyzed insurance claims from nearly 127,000 overweight or obese adults who started these medications between 2019 and 2024. Only a quarter stayed on their initial drug for a full year, with about one in five switching due to side effects, access issues, or insurance changes. Those who switched were more likely to continue treatment, with 36 percent persisting compared to 21 percent of non-switchers. Senior researcher Sarah Messiah noted that switching should be seen as a normal part of long-term obesity care, emphasizing the need to adapt strategies for sustainable results.Meanwhile, a Cleveland Clinic study published on March 12 in Diabetes, Obesity and Metabolism examined nearly 8,000 patients who stopped semaglutide, the active ingredient in Ozempic, or tirzepatide after three to twelve months. Patients treated for obesity lost an average of 8.4 percent of body weight before stopping and regained just 0.5 percent one year later. Those with type 2 diabetes lost 4.4 percent initially and continued losing an additional 1.3 percent. Lead researcher Hamlet Gasoyan explained that many restart the original drug, switch to alternatives, or pursue lifestyle changes, leading to better real-world outcomes than clinical trials where weight regain is higher without follow-up.Oprah Winfrey has been at the center of recent buzz after appearing slimmer at Paris Fashion Week earlier this month, as covered by Moneycontrol on March 8 and Fox News. Fans speculated about Ozempic use, noting her casual jeans and jacket look with a sleek ponytail. Winfrey has previously confirmed using GLP-1 medications, describing how they quieted constant food thoughts and helped her eat only when hungry. She combined this with strength training, now holding a one-minute plank, and views obesity as a genetic condition beyond willpower alone.These developments highlight evolving strategies for GLP-1 drugs in weight management, showing flexibility and persistence pay off for many.Thanks for tuning in, listeners. Please subscribe, and remember, this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Elijah gets you caught up on his past week & answers your email questions.

Oprah Winfrey and Maria Shriver have shared more than 40 years of friendship, built on loyalty, honesty, and showing up for one another. In this conversation from October 2021, they join Hoda to talk about navigating births, deaths, marriage, divorce, and evolving as people while staying connected through it all. Plus, Winfrey reflects on one of the darkest periods of her life and why learning to cherish the people who stand beside you matters most. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Elijah getsv you caught up on his past week, weekend, & answers your email questions.

Novo Nordisk announced on Tuesday that it plans to cut the list prices of its blockbuster weight-loss and diabetes drugs Ozempic and Wegovy by up to fifty percent starting January first, twenty twenty-seven. The Danish company stated that various doses of these medications, which contain the active ingredient semaglutide, will drop to six hundred seventy-five dollars per month. This represents a fifty percent reduction for Wegovy and a thirty-five percent cut for Ozempic, with the same price applying to Rybelsus pills. Fox Business reports that Novo Nordisk executive Jamey Millar explained the move aims to help more than one hundred million Americans with obesity and thirty-five million with type two diabetes by lowering out-of-pocket costs, especially for those on high-deductible health plans. CBS News notes this comes amid fierce competition from rivals like Eli Lillys Mounjaro and Zepbound, as well as cheaper compounded versions from telehealth providers. The price slash will align with lower Medicare rates for older Americans but will not affect direct-to-consumer prices, where Wegovy already sells for three hundred forty-nine dollars.In related news, Oprah Winfrey has shared fresh insights on her use of GLP-one medications like those in the Ozempic family. In a recent NBC Connecticut discussion tied to her book Enough, co-authored with Yale Obesity Research Center director Doctor Ania M. Jastreboff, Winfrey reflected on stopping the shots cold turkey on her seventieth birthday in January twenty twenty-four after gaining clarity that obesity drives overeating due to the bodys enough point, a genetically influenced weight set point. She tried maintaining her loss through diet and exercise alone but regained twenty pounds over twelve months, realizing these drugs are a lifelong tool, much like blood pressure medication. Doctor Jastreboff emphasized in the interview that the medications recalibrate this enough point in the brain, reducing hunger signals and fat storage, countering the bodys drive to regain weight. Winfrey, who pays out of pocket for friends unable to afford the shots, urges ending shame around obesity, calling it a disease not a personal failing. She stresses combining drugs with healthy habits for sustainable health, not just looks.These developments highlight growing accessibility and realism around GLP-one drugs amid evolving expert views.Thanks for tuning in, listeners, please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Elijah gets you caught up on his past week, & answers your questions about autism.

Slop Citizens: Please welcome for the first time ever to Slop City Podcast..........the very funny, Charlie Winfrey! Charlie is a longtime friend/pos of ours. We've known him since day 1 of starting comedy at the Westport Funnybone! He is one of us and we love him. A good ole St Louis #hoosier You can get more Charlie Winfrey in your life by subscribing to HIS podcast: https://www.youtube.com/@WithFrankieAndChuck Slop Citizens, please leave us a comment! It helps us beyond your imagiiiiiiiinaaaaAAtion!

Elijah gets you caught up on his past week, & answers your email questions.

Recent news highlights ongoing developments in weight loss treatments like Ozempic, with fresh insights from clinical reviews and patient experiences. On February 11, 2026, Cochrane reviews commissioned by the World Health Organization analyzed GLP-1 drugs including semaglutide, sold as Ozempic and Wegovy. These studies, drawing from dozens of trials with tens of thousands of participants, show semaglutide leads to an average weight loss of about 11 percent after six to 18 months when paired with diet and exercise. Tirzepatide, marketed as Mounjaro and Zepbound, achieved around 16 percent loss in similar periods. Researchers note these benefits persist during treatment but emphasize limited long-term safety data, common side effects like nausea, and heavy industry funding in most trials. Cochrane reports highlight the need for independent studies on heart health, quality of life, and global access, as high costs limit use in lower-income regions.A Rutgers Health study published this week in the Journal of Medical Internet Research examined why Ozempic users stick with it despite side effects. Analyzing online reviews, researchers found perceived effectiveness in curbing appetite and shedding pounds outweighs issues like stomach upset for most. Lead author Abanoub Armanious noted that everyday users prioritize real results over hype from celebrities or social media. Separately, Weill Cornell Medicine researchers reported on February 11 that GLP-1 drugs like tirzepatide may lower risks of diabetic retinopathy progression in diabetes patients, countering earlier concerns.Oprah Winfrey continues to speak openly about her GLP-1 use, as covered in recent AOL articles. The media icon, who lost about 50 pounds starting in 2023 but regained 20 after briefly stopping, now views these medications as a lifelong tool like blood pressure drugs. Promoting her book Enough, Winfrey shared on The View and her podcast that the drugs silenced constant food thoughts, freeing her from self-blame. She told listeners obesity is not a willpower failure but a brain-driven condition, urging others to seek medical options without shame. Winfrey, who covers costs for friends, also noted reduced alcohol cravings as a bonus.Meanwhile, excitement builds around Eli Lillys oral pill orforglipron, an injectable-free alternative to Ozempic. Phase 3 trials like ATTAIN-1 showed 12.4 percent average weight loss over 72 weeks, with many maintaining results after switching from shots. Walk In reports it could launch in Canada soon, offering daily convenience without fasting, though generics of semaglutide arrive mid-2026 for affordability.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Elijah gets you caught up on his weekend, & this week he answers questions from me ( his producer) about a variety of topics! Be sure to tune in!

In the past week, weight loss drugs like Ozempic, Wegovy, and Mounjaro have reshaped global conversations on obesity, marking 2026 as a potential turning point. Firstpost reports that these GLP-1 drugs, originally developed for type two diabetes, trigger significant weight loss by curbing appetite, leading to falling obesity rates in the United States for the first time since the 1980s. One in eight Americans now uses these medications, sparking changes across industries. Supermarkets see snack sales drop by up to 10 percent, with less demand for chips, cookies, and soda, while fresh fruits and vegetables gain popularity. Companies like Nestle launch GLP-1 friendly meals, and restaurants shrink portion sizes. Alcohol consumption dips among users, boosting non-alcoholic drink sales. Retailers face challenges as smaller clothing sizes sell out, leaving billions in unsold larger stock, and gyms adapt with strength training programs to counter muscle loss, which can account for 39 to 40 percent of total weight shed.Oprah Winfrey has been candid about her experiences with these drugs. In recent interviews covered by AOL and Fox News, the 71-year-old media icon revealed dropping from 211 pounds to 155 pounds using a GLP-1 medication alongside daily hiking and resistance training. She quit the drug after six months but regained 20 pounds despite strict diet and exercise, concluding it is a lifetime commitment, much like blood pressure medication. On The Oprah Podcast and The View, Winfrey discussed overcoming shame from decades of public weight ridicule, including comedian jokes she once accepted as deserved. Co-authoring the book Enough with Yale endocrinologist Dr. Ania Jastreboff, she challenged myths of willpower, likening obesity to a brain-driven disease that silences food noise. Guest stories highlighted persistent shaming regardless of method, with Jastreboff urging focus on health over blame.Yet experts raise cautions. University of Cambridge research in Obesity Reviews warns that without nutrition guidance, users risk deficiencies in protein, vitamins, and minerals, plus muscle loss leading to fatigue or osteoporosis. UCLs Dr. Adrian Brown and colleagues recommend bariatric-style care, prioritizing nutrient-dense foods. George Mason Universitys Martin Binks calls for holistic strategies with dietitians and exercise support, noting uneven access due to cost.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Elijah gets you caught up on his past week, and answers questions this week from listeners seeking direction as they continue to chase their dreams.

Oprah Winfrey turns 72 today, marking a career that reshaped American media and cultural conversation. From redefining daytime television to building the OWN network and amplifying education, philanthropy and political engagement, Winfrey's influence extends far beyond entertainment. Her work helped normalize empathy, vulnerability and storytelling as tools for connection, accountability and liberation — a legacy that continues to shape generations. Subscribe to our newsletter to stay informed with the latest news from a leading Black-owned & controlled media company: https://aurn.com/newsletter Learn more about your ad choices. Visit megaphone.fm/adchoices

Oprah Winfrey turns 72 today, marking a career that reshaped American media and cultural conversation. From redefining daytime television to building the OWN network and amplifying education, philanthropy and political engagement, Winfrey's influence extends far beyond entertainment. Her work helped normalize empathy, vulnerability and storytelling as tools for connection, accountability and liberation — a legacy that continues to shape generations. Subscribe to our newsletter to stay informed with the latest news from a leading Black-owned & controlled media company: https://aurn.com/newsletter Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The landscape of weight loss treatment in America is shifting dramatically as glucagon-like peptide-one receptor agonists, or GLP-1s, continue to dominate conversations about obesity management. According to a Pew Research Center report from January 2026, thirteen states now cover GLP-1s for obesity treatment under Medicaid, though this represents progress tempered by significant setbacks. California, New Hampshire, Pennsylvania, and South Carolina stopped covering these medications as of January first, citing rising costs that have strained state budgets. The medications, which include popular drugs like Ozempic and Wegovy, have seen explosive growth, with Novo Nordisk reporting thirty-one point one billion dollars in combined revenue from these three drugs in 2024, nearly triple the eleven point nine billion from 2022.Public awareness of these medications continues to surge. According to Pew Research data from early 2025, about fifty-three percent of Americans say they hear or read about Ozempic, Wegovy, and similar drugs extremely or very often. Yet Americans remain divided on appropriate use. While fifty-three percent of those familiar with these medications see them as good options for people with obesity or weight-related health conditions, only twelve percent view them as appropriate for people who simply want to lose weight without existing health issues.Oprah Winfrey has been particularly vocal about her GLP-1 journey, recently speaking with CBS about her experience with these medications. In an interview from January 12, 2026, the seventy-one-year-old media mogul described how the medication eliminated what she calls "food noise" within hours of her first dose. She expressed deep regret that she did not discover this treatment option in 2013, speaking emotionally about the wasted years of shame and sadness surrounding her weight struggles. Winfrey now views obesity as a disease rather than a personal failure, a perspective shift that has transformed her relationship with these medications. After taking herself off the drug for a year to prove she could manage without it, she gained twenty pounds and has since recommitted to the treatment, recognizing that like her blood pressure medication, these drugs represent a long-term management tool she needs to maintain her health.The first week of 2026 has highlighted the complex reality of weight loss medication access in America. While newer treatments continue to emerge and awareness spreads, insurance coverage remains inconsistent and often declining. The tension between rising demand, limited access through public programs, and growing pharmaceutical revenues underscores the ongoing challenges in making these transformative treatments available to all Americans who need them.Thanks for listening. Please subscribe and remember, this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot AI. We'll be back next week with more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Elijah gets you caught up on his past week dealing with the flu, & answers your email questions.

Elijah spends this episode talking about Dr. Martin Luther King Jr. Be sure to tune in.

Health Canada approved the first glucagon-like peptide one daily pill, Rybelsus, on Monday for adults with type two diabetes who face high risks of heart disease. This semaglutide pill, made by the same company behind injectable Ozempic and Wegovy, aims to improve blood sugar levels alongside diet and exercise while cutting chances of heart attacks, strokes, or death from cardiovascular events. Company trials with over nine thousand six hundred fifty patients showed it lowered those risks compared to a placebo. Unlike prior GLP one drugs in Canada, all injectables until now, this offers a convenient oral option, though experts note it may need higher doses since stomach acids break down some of the peptide, making injections potentially more effective for weight loss.Recent studies highlight challenges with these medications. A review in the British Medical Journal, published this week, analyzed sixty-three trials involving more than nine thousand people and found users regain weight at about zero point four kilograms per month after stopping GLP one drugs, with heart benefits vanishing too. In the United States, the food and drug administration approved an oral Wegovy pill last month, now available for around one hundred forty-nine United States dollars monthly through places like Amazon Pharmacy.Oprah Winfrey, seventy-one, shared candid thoughts on GLP one medications this week during appearances on CBS Sunday Morning and The View. She called them a vital tool for managing obesity, a disease she now views without shame or self-blame. Winfrey said the constant food noise in her mind vanished hours after her first dose, freeing her from obsession despite still enjoying food. She regrets not discovering them in two thousand thirteen, lamenting wasted years of sadness, and admitted gaining twenty pounds in a year after stopping to test her willpower, proving to her it is a lifelong need like blood pressure medicine. Promoting her new book with doctor Ania Jastreboff, she stressed obesity causes overeating, not the reverse, and urged ending blame, even covering costs for friends who cannot afford it.Analysts at Jefferies noted on January twelfth that widespread use of weight loss drugs like Ozempic could save major United States airlines up to five hundred eighty million dollars in fuel this year, as lighter passengers cut jet fuel needs by up to one point five percent. In Canada, semaglutide patents expired this month, paving the way for cheaper generics to boost access.Thanks for tuning in, listeners, please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this episode, Sunny Hostin and executive producer Brian Teta discuss Oprah Winfrey's appearance on ‘The View.' Hostin shares about looking up to Winfrey when she was a young woman and opens up about her journey with weight loss, which Winfrey discusses in her new book, 'Enough: Your Health, Your Weight, and What It's Like to Be Free.' Hostin touches on constitutional rights during police encounters and critiques the actions of ICE agents. We're honored to be nominated by the NAACP for Outstanding Talk Series at the 57th NAACP Image Awards! Cast your vote today: vote.naacpimageawards.net Learn more about your ad choices. Visit podcastchoices.com/adchoices

Recent research from Cornell University reveals that weight-loss drugs like Ozempic and Wegovy are significantly reducing how much Americans spend on food. According to the study published in the Journal of Marketing Research, households cut grocery spending by an average of 5.3 percent within six months of starting these GLP-1 receptor agonist medications, with higher-income families seeing drops over 8 percent. Fast-food and coffee shop spending fell by about 8 percent too. The biggest declines hit savory snacks, sweets, baked goods, and cookies, down around 10 percent, while yogurt and fresh fruit purchases rose modestly. Sylvia Hristakeva, an assistant professor of marketing at Cornell, noted that these changes persist for at least a year among ongoing users but fade after stopping.Oprah Winfrey shared her personal experiences with GLP-1 medications in recent interviews. Business Insider reports that the 71-year-old media icon regrets not discovering these drugs earlier, calling them a vital tool for managing obesity as a chronic disease. She described how the constant food noise in her head vanished within hours of her first dose, leaving her indifferent to food obsessions despite still enjoying it. Winfrey told CBS Sunday Morning she wept thinking of years wasted on shame, believing her struggles stemmed from personal failure rather than biology. After stopping for a year to test herself, she gained 20 pounds, proving to her that the medication is essential, much like blood pressure drugs.On NBC's Today show, Winfrey discussed side effects from her GLP-1 use while promoting her new book with Yale's Dr. Ania M. Jastreboff. She experienced constipation but no nausea or diarrhea, managing it by drinking a gallon of water daily before 4 p.m. to keep her kidneys happy. The book aims to shift views on obesity, comparing stigma around these drugs to past misconceptions about alcoholism.Experts predict further evolution for these treatments. Fox News Digital spoke with specialists forecasting 2026 shifts, including GLP-1s as multi-system metabolic modulators targeting heart, kidney, and liver health beyond just weight. Novo Nordisk launched a daily oral semaglutide pill nationwide on January 5, offering a convenient non-injection option. A new Oxford University study across 37 trials with over 9,000 adults found weight regain averages 0.4 kilograms per month after stopping these drugs.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Iran's exiled Crown Prince Reza Pahlavi has lived in the U.S. for decades, but is casting himself as part of the future of Iran amid protests. He wants President Trump to intervene "so this regime finally collapses and puts an end to all the problems that we are facing." Pahlavi said his nearly half century in the U.S. is an asset to replace the Islamic Republic with what he called a "democratic alternative." Elon Musk's AI chatbot Grok is facing intense criticism, accused of allowing X users to generate sexually explicit images of real women and children. One of the alleged victims is Ashley St. Clair, the mother of one of Musk's children. She said she discovered people used Grok to generate and publish sexualized deepfake images without her permission and share them on X. Musk has not responded to a request for comment. Oprah Winfrey is opening up about her personal weight journey. In her new book, "Enough: Your Health, Your Weight and What It's Like To Be Free," she reveals she went from blaming and shaming herself to transforming her health. Winfrey and Dr. Ania Jastreboff, the book's co-author, join "CBS Mornings" to talk about ending the shame around weight, diet culture and GLP-1 medications. You can purchase Winfrey and Jastreboff's book by clicking here: https://amzn.to/3N2zRSu Francois Arnaud joins "CBS Mornings" to talk about the popular series "Heated Rivalry," based on the "Game Changers" book series. It follows rising hockey stars Shane Hollander and Ilya Rozanov. What begins as a fling between two rivals turns into a yearslong journey of love, denial and self discovery. Arnaud plays Scott Hunter, a closeted gay professional hockey player in the same league who has fallen in love with a smoothie shop worker. He talks about the message in the series and how it developed into a hit show. Content creator Melani Sanders shares in her viral videos all the things menopausal women no longer care about. She speaks to "CBS Mornings" about her new book, "The Official We Do Not Care Club Handbook: A Hot-Mess Guide for Women in Perimenopause, Menopause, and Beyond Who Are Over It" and how one viral video started a movement. You can purchase Sanders' book by clicking here: https://amzn.to/3YUHay3 To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Elijah gets you caught up on his first full week of the new year and answers questions from a couple of loya listeners.

Elijah kicks off the New Year getting you caught up on his mini break. He also answers your email questions.

Elijah wraps up 2025 answering your email questions and getiing you caught up on his holiday season!

In this episode, the moms welcome back Eli Winfrey! Eli is an author, veteran, autism advocate, podcast host, and founder of Team Winfrey, an organization focused on making a positive impact on others. Eli discusses ways to create self-care practices for busy parents and takes time to discuss the male perspective as they engage in parenting a child on the autism spectrum. Join us for this meaningful discussion with Eli. His life experiences are unique and purposeful, and we are so thankful he took the time to talk with us. We are deeply grateful for your support and look forward to sharing this episode with you! Thank you for listening and connecting with us!Links to Welcome to Holland by Emily Perl Kingsley and the Holland-Schmolland by Laura Krueger Crawford as discussed in the conversation with Eli Winfrey. https://www.emilyperlkingsley.com/welcome-to-hollandhttps://www.txp2p.org/Media/family-stories/Holland_Schmolland.pdfTo learn more about Eli Winfrey and his work go to:www.Teamwinfrey.orgIf you like our podcast, please share, review, and subscribe! You can find us at:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Navigating Adult Autism on Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Navigatingadultautismpodcast on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Navigatingadultautism.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠You can also find Heather Woodring write about her son Zachary at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Everyday Adventures with Zachary on Facebook⁠

Elijah is back & he gets you caught up on his time away, while also answering your email questions.

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeGod loves marriage, and abhors divorce. Oprah WinfreyEpisode Links:Relationship coach blames Oprah for pushing family estrangement 'for decades'; Expert says Winfrey helped normalize 'cutoff culture' as study shows a third of Americans are estranged from familyBREAKING: High Court Judge blocks Enoch Burke's family from courtroom.BREAKING: Florida AG sues WPATH, American Academy of Pediatrics, and The Endocrine Society for m*tilating kids in the name of “gender affirming care.”We wrote the HHS review on treatment for minors with gender dysphoria. We hope our critics actually read our report; Some may be skeptical of our findings, but we believe that our work speaks for itselfWhen we critique Trump, we often hear, “But where were your critiques of Biden?” Here's the difference: the Biden administration didn't use Jesus, the Bible, or Christian language to justify its policies. MAGA does, and large parts of the evangelical church cheer it on. Any administration that uses Christianity to defend something blatantly unchristian will get a Holy Post call-out. If you think it's a sin to have an abortion, then don't have an abortion." The Rev. Dr. Sarah Halverson-Cano of IUCC get teary-eyed at the thought that her daughter and granddaughter WON'T have access to abortion and "reproductive justice."

Elijah gets you caught up on his past week, & answers your email questions.

Elijah gets you caught up on his past weekend, talks about the importance of GIVING TUESDAY, & answers your email questions.

In this episode, the moms welcome Eli Winfrey! Eli is an author, veteran, autism advocate, podcast host, and founder of Team Winfrey, an organization focused on making a positive impact on others. Eli shares with us the experiences that shaped his purpose and drive to help the autism community and many others. Join us for this meaningful discussion with Eli. His life experiences are unique and purposeful, and we are so thankful he took the time to talk with us. We are deeply grateful for your support and can't wait to share this inspiring episode with you! Thank you for listening in and connecting with us!To learn more about Eli Winfrey and his work go to:https://www.teamwinfrey.org/If you like our podcast, please share, review, and subscribe! You can find us at:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Navigating Adult Autism on Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Navigatingadultautismpodcast on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Navigatingadultautism.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠You can also find Heather Woodring write about her son Zachary at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Everyday Adventures with Zachary on Facebook

The popular online game, Roblox, is being sued by multiple state attorneys general, who claim online predators can groom, extort and exploit kids they meet on the platform. In an exclusive interview with CBS News, a father says his son became a victim, despite using the game's parental controls. The chief safety officer at Roblox said the platform has rolled out over 100 new safety features this year, adding, "we take every case of harm extremely seriously." "Podcrushed" hosts Penn Badgley, Sophie Ansari and Nava Kavelin join "CBS Mornings" to discuss their new book "Crushmore," a collection of personal essays about adolescence, friendship and growing up. Oprah Winfrey called Megha Majumdar one of her favorite authors, praising "A Guardian and a Thief" as a novel unlike any other. Winfrey selected it as her latest book club pick. Set in Kolkata, India, the story follows two families fighting to protect their children amid climate change and scarcity. The popular online game, Roblox, is being sued by multiple state attorneys general, who claim online predators can groom, extort and exploit kids they meet on the platform. In an exclusive interview with CBS News, a father says his son became a victim, despite using the game's parental controls. The chief safety officer at Roblox said the platform has rolled out over 100 new safety features this year, adding, "we take every case of harm extremely seriously." Oscar winner Reese Witherspoon and bestselling author Harlan Coben join "CBS Mornings" to discuss their new thriller, "Gone Before Goodbye." The book marks Witherspoon's debut as a novelist and Coben's first collaboration, following an Army surgeon entangled in a web of spies, lies and personal struggles. New York Times bestselling author Jason Reynolds joins "CBS Mornings" to discuss "Coach," the latest addition to his popular "Track" series. The new story explores the childhood of Coach Otis Brody, a boy with dreams of Olympic glory. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Original airdate: July 11, 2023 Have you ever experienced something so inexplicable that you knew it had to be more than just a coincidence? Experiences like this make us believe that a benevolent force of energy is available to guide and direct our lives. My guest, Cheryl Richardson, calls this energy grace. She believes that every event we experience, and every person we meet has been put in our path for a reason. She's here to speak more about the transformational power of grace. Cheryl Richardson is the NYT bestselling author of several books, including, Take Time for Your Life, Life Makeovers and The Unmistakable Touch of Grace. She was the first president of the International Coach Federation. Her work has been covered widely in the media, including Good Morning America, The Today Show, New York Times and O Magazine. She was the team leader for the Lifestyle Makeover Series on the Oprah Winfrey Show and accompanied Ms. Winfrey on the “Live Your Best Life” nationwide tour. During our conversation, Cheryl and I discuss the significance of coincidences and how to recognize and interpret them through the lens of grace. She also talks about tapping into grace so that we can feel vibrant and balanced as we age. **Important note: Certain segments of the audio are disrupted because of an unstable internet connection. We apologize for any inconvenience caused.**

DallasCowboys.com Insider Mickey Spagnola joins the show to talk all things Cowboys including Perrion Winfrey heading to injured reserve.